{"entity":{"id":"nct06194656","kind":"trial","name":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Cetuximab in head and neck squamous cell carcinoma, run by Shanghai Institute Of Biological Products, now recruiting.","summary":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06194656 by Shanghai Institute Of Biological Products, with 81 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-07-30. Interventions recorded: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06194656","url":"https://clinicaltrials.gov/study/NCT06194656"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06194656","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of SIBP-03 Injection Combined With Cetuximab in Patients With Recurrent/Metastatic Advanced Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)","sponsor":"Shanghai Institute Of Biological Products","enrolled":81,"outcomes":[]},"route":"/trials/nct06194656/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}]}}